LT3706739T - Riluzolo provaisto naudojimas ataksijų gydymui - Google Patents

Riluzolo provaisto naudojimas ataksijų gydymui

Info

Publication number
LT3706739T
LT3706739T LTEPPCT/US2018/060232T LTUS2018060232T LT3706739T LT 3706739 T LT3706739 T LT 3706739T LT US2018060232 T LTUS2018060232 T LT US2018060232T LT 3706739 T LT3706739 T LT 3706739T
Authority
LT
Lithuania
Prior art keywords
ataxia
treatment
riluzole prodrug
riluzole
prodrug
Prior art date
Application number
LTEPPCT/US2018/060232T
Other languages
English (en)
Inventor
Vladimir Coric
Robert Berman
Melissa BEINER
Gilbert L'ITALIEN
Original Assignee
Biohaven Therapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66438598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3706739(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biohaven Therapeutics Ltd. filed Critical Biohaven Therapeutics Ltd.
Publication of LT3706739T publication Critical patent/LT3706739T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2018/060232T 2017-11-12 2018-11-11 Riluzolo provaisto naudojimas ataksijų gydymui LT3706739T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584856P 2017-11-12 2017-11-12
US201862717948P 2018-08-13 2018-08-13
PCT/US2018/060232 WO2019094851A1 (en) 2017-11-12 2018-11-11 Use of riluzole prodrugs to treat ataxias

Publications (1)

Publication Number Publication Date
LT3706739T true LT3706739T (lt) 2024-12-27

Family

ID=66438598

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/060232T LT3706739T (lt) 2017-11-12 2018-11-11 Riluzolo provaisto naudojimas ataksijų gydymui

Country Status (26)

Country Link
US (3) US20210023061A1 (lt)
EP (4) EP3706739B1 (lt)
JP (2) JP7352542B2 (lt)
KR (2) KR20200103658A (lt)
CN (1) CN112292127A (lt)
AU (1) AU2018364749C1 (lt)
BR (1) BR112020009173A2 (lt)
CA (1) CA3082096A1 (lt)
DK (2) DK3706739T3 (lt)
ES (1) ES2996892T3 (lt)
FI (2) FI3706739T3 (lt)
HR (1) HRP20241675T1 (lt)
HU (1) HUE070302T2 (lt)
IL (1) IL274532B2 (lt)
LT (1) LT3706739T (lt)
MD (1) MD3706739T2 (lt)
MX (2) MX2020004678A (lt)
PH (1) PH12020550583A1 (lt)
PL (1) PL3706739T3 (lt)
PT (2) PT3706739T (lt)
RS (1) RS66277B1 (lt)
SG (1) SG11202004332XA (lt)
SI (1) SI3706739T1 (lt)
SM (1) SMT202500022T1 (lt)
WO (1) WO2019094851A1 (lt)
ZA (1) ZA202002626B (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62915B1 (sr) 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
WO2018031707A1 (en) 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
US20250127789A1 (en) * 2021-11-04 2025-04-24 Skyhawk Therapeutics, Inc. Compositions useful for modulating splicing
WO2023230451A2 (en) * 2022-05-23 2023-11-30 Biohaven Therapeutics Ltd. Methods of treating spinocerebellar ataxias
WO2026078657A1 (en) 2024-10-10 2026-04-16 Biohaven Therapeutics Ltd. Prodrugs of riluzole

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US5631023A (en) 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
AU736912B2 (en) 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
DE69834255T2 (de) 1997-07-25 2006-09-28 Alpex Pharma S.A. Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
EP1485296B1 (en) 2002-02-13 2011-07-20 Michael K. Weibel Drug dose - form and method of manufacture
DE50304744D1 (de) * 2003-04-28 2006-10-05 Biofrontera Bioscience Gmbh Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP2009521523A (ja) 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8485861B2 (en) 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
RS62915B1 (sr) 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena

Also Published As

Publication number Publication date
PH12020550583A1 (en) 2021-05-31
SG11202004332XA (en) 2020-06-29
KR20250034521A (ko) 2025-03-11
EP3706739A1 (en) 2020-09-16
AU2018364749A1 (en) 2020-07-02
CA3082096A1 (en) 2019-05-16
EP3706739A4 (en) 2021-08-04
AU2018364749B2 (en) 2023-11-09
IL274532B1 (en) 2024-01-01
ES2996892T3 (en) 2025-02-13
US20210023061A1 (en) 2021-01-28
AU2018364749C1 (en) 2024-02-15
MX2020004678A (es) 2020-08-13
HUE070302T2 (hu) 2025-05-28
DK4483956T3 (da) 2026-03-23
EP4699619A2 (en) 2026-02-25
EP4483956B1 (en) 2025-12-31
CN112292127A (zh) 2021-01-29
NZ765220A (en) 2023-11-24
JP2021502392A (ja) 2021-01-28
MX2023012640A (es) 2023-11-08
MD3706739T2 (ro) 2025-02-28
US12102618B2 (en) 2024-10-01
WO2019094851A1 (en) 2019-05-16
EP4483956A3 (en) 2025-03-19
KR20200103658A (ko) 2020-09-02
SMT202500022T1 (it) 2025-03-12
PL3706739T3 (pl) 2025-03-10
RS66277B1 (sr) 2025-01-31
SI3706739T1 (sl) 2025-03-31
PT3706739T (pt) 2024-12-04
PT4483956T (pt) 2026-03-16
JP2023175823A (ja) 2023-12-12
EP4483956A2 (en) 2025-01-01
EP3706739B1 (en) 2024-10-16
JP7352542B2 (ja) 2023-09-28
US20230355592A1 (en) 2023-11-09
FI3706739T3 (fi) 2024-12-27
BR112020009173A2 (pt) 2020-11-03
ZA202002626B (en) 2025-02-26
FI4483956T3 (fi) 2026-03-16
IL274532A (en) 2020-06-30
DK3706739T3 (da) 2024-12-02
US20230390252A1 (en) 2023-12-07
IL274532B2 (en) 2024-05-01
HRP20241675T1 (hr) 2025-02-14
EP4696324A2 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
IL278080A (en) Riluzole prodrugs and their use
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
MA45192A (fr) Traitement d'association
LT3706739T (lt) Riluzolo provaisto naudojimas ataksijų gydymui
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
PL3265053T3 (pl) Sposoby leczenia skóry
EP3532092A4 (en) IMMUNOGLOBULINS AND USES THEREOF
PL3681872T3 (pl) Podstawione heteroarylem beta-hydroksyetylaminy do stosowania w leczeniu hiperglikemii
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
DK3474802T3 (da) Medicinsk forbinding
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PT3185957T (pt) Patisiran para utilização no tratamento de amoloidose mediada por transtirretina
PL3481846T3 (pl) 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
EP3556368A4 (en) THERAPEUTIC FOR ONYCHOMYCOSIS
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
EP3858943A4 (en) Surface treatment agent
HUE056138T2 (hu) Azasetron a halláskárosodás kezelésében való felhasználásra
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
EP3324894A4 (en) LATERAL AND MEDIAL SWITCHING KNEE PROSTHESIS
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
IL251903B (en) Apilimod for use in the treatment of colorectal cancer
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
DK3606926T3 (da) Heteroaromatiske forbindelser anvendelige i terapi